Symbols

CMPS

COMPASS Pathways·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Stock Price Surged Significantly

Consensus Rating "Buy"

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CMPS

Compass Pathways Plc

A UK developer of psilocybin therapy for the treatment of resistant depression

Industry

Pharmaceutical

Established Date

Listing Date

09/18/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

156

Fiscal Year Ends

12-31

Website

www.compasspathways.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

33 Broadwick Street London W1F 0DQ United Kingdom

Business

Introduction

COMPASS Pathways plc was originally incorporated as a private limited company under the laws of England and Wales in June 2020. The company is a biotechnology company dedicated to accelerating patient access to innovative evidence-based mental health therapies. The company is pioneering a new paradigm for treating mental health conditions with a focus on rapid and durable responses by developing their investigational COMP 360 psilocybin treatment, which may be the first of its kind. COMP 360 is their proprietary psilocybin formulation, which includes their pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity.

Company Financials

EPS

CMPS has released its 2025 Q4 earnings. EPS was reported at -1, versus the expected -0.4, missing expectations. The chart below visualizes how CMPS has performed over recent quarters, highlighting trends in earnings surprises.